trending Market Intelligence /marketintelligence/en/news-insights/trending/0z00xuCwK__LiwAvWiEoIA2 content esgSubNav
In This List

EyeNovia prices common stock offering to fund clinical trials


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

EyeNovia prices common stock offering to fund clinical trials

Eyenovia Inc. priced an offering of 1.2 million common shares at $2.45 apiece.

The offering is expected to close by Dec. 21 with National Securities Corp. acting as the sole book-running manager.

The New York-based maker of eye treatments granted the underwriter a 45-day option to buy up to an additional 180,000 shares to cover any over-allotments.

The company expects gross proceeds of about $2.9 million excluding the exercise of the underwriter's option, and about $3.4 million assuming full exercise of the option.

EyeNovia plans to use the proceeds to start phase 3 trials for its therapies MicroPine and MicroProst.

MicroPine is a treatment for myopia, or nearsightedness, while MicroProst is a therapy for chronic angle closure glaucoma, an eye condition affecting the optic nerve.